Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Caravaca-Fontán, F; Stevens, K; Padrón, M; Huerta, A; Montomoli, M; Villa, J; González, F; Vega, C; López, Mendoza, M; Fernández, L; Shabaka, A; Rodríguez-Moreno, A; Martín-Gómez, A; Labrador, PJ; Molina, Andújar, A; Prados, Soler, MC; Martín-Penagos, L; Yerovi, E; Medina, Zahonero, L; De, La, Flor, JC; Mon, C; Ibernon, M; Rodríguez, Gómez, A; Miquel, R; Sierra, M; Mascarós, V; Luzardo, L; Papasotiriou, M; Arroyo, D; Verdalles, Ú; Martínez-Miguel, P; Ramírez-Guerrero, G; Pampa-Saico, S; Moral, Berrio, E; Canga, JLP; Tarragón, B; Fraile, Gómez, P; Regidor, D; Relea, J; Xipell, M; Andrades, Gómez, C; Navarro, M; Álvarez, Á; Rivas, B; Quintana, LF; Gutiérrez, E; Pérez-Valdivia, MÁ; Odler, B; Kronbichler, A; Geddes, C; Anders, HJ; Floege, J; Fernández-Juárez, G; Praga, M.
Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.
Nephrol Dial Transplant. 2024; 39(2):328-340
Doi: 10.1093/ndt/gfad175
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Odler Balazs
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: The role of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the management glomerular/systemic autoimmune diseases with proteinuria in real-world clinical settings is unclear. METHODS: This is a retrospective, observational, international cohort study. Adult patients with biopsy-proven glomerular diseases were included. The main outcome was the percentage reduction in 24-h proteinuria from SGLT2i initiation to 3, 6, 9 and 12 months. Secondary outcomes included percentage change in estimated glomerular filtration rate (eGFR), proteinuria reduction by type of disease and reduction of proteinuria ≥30% from SGLT2i initiation. RESULTS: Four-hundred and ninety-three patients with a median age of 55 years and background therapy with renin-angiotensin system blockers were included. Proteinuria from baseline changed by -35%, -41%, -45% and -48% at 3, 6, 9 and 12 months after SGLT2i initiation, while eGFR changed by -6%, -3%, -8% and -10.5% at 3, 6, 9 and 12 months, respectively. Results were similar irrespective of the underlying disease. A correlation was found between body mass index (BMI) and percentage proteinuria reduction at last follow-up. By mixed-effects logistic regression model, serum albumin at SGLT2i initiation emerged as a predictor of ≥30% proteinuria reduction (odds ratio for albumin <3.5 g/dL, 0.53; 95% CI 0.30-0.91; P = .02). A slower eGFR decline was observed in patients achieving a ≥30% proteinuria reduction: -3.7 versus -5.3 mL/min/1.73 m2/year (P = .001). The overall tolerance to SGLT2i was good. CONCLUSIONS: The use of SGLT2i was associated with a significant reduction of proteinuria. This percentage change is greater in patients with higher BMI. Higher serum albumin at SGLT2i onset is associated with higher probability of achieving a ≥30% proteinuria reduction.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Humans - administration & dosage
- Middle Aged - administration & dosage
- Cohort Studies - administration & dosage
- Kidney Diseases - complications
- Glomerulonephritis - drug therapy, complications
- Proteinuria - etiology, complications
- Serum Albumin - administration & dosage
- Sodium - administration & dosage
- Glucose - administration & dosage
- Diabetes Mellitus, Type 2 - complications
- Find related publications in this database (Keywords)
- body mass index
- estimated glomerular filtration rate
- glomerular disease
- proteinuria
- sodium-glucose cotransporter 2 inhibitors